Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ½Å°æÁúȯ > U.S. Multiple Sclerosis Markets
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

U.S. Multiple Sclerosis Markets

¸®¼­Ä¡»ç Frost & Sullivan
¹ßÇàÀÏ 2007³â 09¿ù »óǰÄÚµå 56326
ÆäÀÌÁö Á¤º¸ 77 Pages
°¡°Ý
US $ 6,000 £Ü 7,149,000 Web Access (Regional License)
US $ 6,500 £Ü 7,744,700 Hard Copy & Web Access (Regional License)


¿µ¹®¸ñÂ÷

Abstract

This research service provides revenue forecasts, market shares, projected prevalence and treated populations, market trends, and existing and emerging therapeutics. There is a competitive and product analysis of the major market participants and products with competitive metrics for major and emerging companies.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • Introduction

2. MARKET INTRODUCTION

Introduction

  • Multiple Sclerosis
  • Scope and Segmentation
  • Research Methodology

Disease Overview

  • Causes of Multiple Sclerosis
  • Classification of Multiple Sclerosis
  • Treatment Options

Market Overview

  • Market Engineering Measurements
  • Market Trends

3. MARKET ANALYSIS

Product Analysis

  • Interferons
  • Copaxone
  • Tysabri
  • Novantrone
  • Pipeline Drugs

Patient Forecasts

  • Total Patient Forecasts
  • Patient Forecast by Product

Revenue Forecasts

  • Total Market Revenue Forecasts
  • Revenue Forecasts by Product

Competitive Analysis

  • Competitive Structure
  • Company Market Share

Competitve Metrics

  • Methodology and Metrics
  • Biogen Idec
  • Teva Pharmaceuticals
  • EMD Serono
  • Bayer Schering Pharma
  • Emerging Companies

4. DECISION SUPPORT DATABASES

Demographic Indicators

  • Total Population

Market Indicators

  • World Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Incidence
  • Pharmaceutical R&D Expenditure
Back to Top